Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors: Systematic review and meta-analysis

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Ocana, Alberto ^a   Vera Badillo, Francisco ^b   Al Mubarak, Mustafa ^b   Templeton, Arnoud J ^b   Corrales Sanchez, Verónica ^a   Diez Gonzalez, Laura ^a   Cuenca Lopez, María D ^a   Seruga, Bostjan ^c   Pandiella, Atanasio ^d   Amir, Eitan ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^b PRINCESS MARGARET HOSPITAL   (Canada)

^c INSTITUTE OF ONCOLOGY   (Slovenia)

^d UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ADOLESCENT; ARTICLE; CANCER LOCALIZATION; CANCER MORTALITY; CANCER SURVIVAL; CHILD; DISEASE ASSOCIATION; ENZYME ACTIVATION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; META ANALYSIS (TOPIC); OVERALL SURVIVAL; PIK3CA GENE; PRESCHOOL CHILD; PROTEIN EXPRESSION; SCHOOL CHILD; SOLID TUMOR; SURVIVAL TIME; SYSTEMATIC REVIEW; UPREGULATION; WESTERN BLOTTING; META ANALYSIS; METABOLISM; NEOPLASM; PATHOLOGY; SIGNAL TRANSDUCTION; SURVIVAL;

HUMANS; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASE; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TOR SERINE-THREONINE KINASES;

EID: 84899706062     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0095219     Document Type: Article

References (40)

1. Amir E, Seruga B, Martinez-Lopez J, Kwong R, Pandiella A, et al.(2011) Oncogenic targets, magnitude of benefit, and market pricing of antineoplastic drugs. J Clin Oncol 29: 2543-2549.
2. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, et al.(2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-92. (Pubitemid 32222155)
3. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, et al.(2010) Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376: 687-97.
4. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, et al.(2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348: 994-1004. (Pubitemid 36302244)
5. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, et al.(2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364: 2507-16.
6. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, et al. (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363: 1693-703.
7. Sawyers CL (2008) The cancer biomarker problem. Nature 452: 548-52.
8. Paik S, Shak S, Tang G, Kim C, Baker J, et al.(2004).A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-26. (Pubitemid 40051905)
9. Engelman JA (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9: 550-62.
10. Courtney KD, Corcoran RB, Engelman JA.(2010). The PI3K pathway as drug target in human cancer. J Clin Oncol 28: 1075-83.
11. Bissler JJ, Kingswood JC, Radzikowska E, Zonnenberg BA, Frost M, et al. (2013) Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet 381: 817-24.
12. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, et al. (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372: 449-56.
13. Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, et al. (2012) Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med 366: 520-9.
14. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, et al. (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356 :2271-81. (Pubitemid 46849157)
15. Ocana A, Amir E, Seruga B, Martin M, Pandiella A (2013) The evolving landscape of protein kinases in breast cancer: Clinical implications. Cancer Treat Rev 39: 68-76.
16. Garcia-Echeverria C, Sellers WR (2008) Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 27: 5511-26.
17. Liberati A, Altman D, Tetzlaff J (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 21; 6(7):e1000100.
18. Deeks JJ, Higgins JPT, Altman D.G, editors Ltd (2006) Analysing and presenting results. Cochrane Handbook for Systematic Reviews of Interventions 4 2 5 In: The Cochrane Library, Chichester, UK, John Wiley & Sons.
19. Li J, Yen C, Liaw D, Podsypanina K, Bose S, et al. (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943-7. (Pubitemid 27148818)
20. Alonso A, Sasin J, Bottini N, Friedberg I, Friedberg I, et al.(2004) Protein tyrosine phosphatases in the human genome. Cell 117: 699-711. (Pubitemid 38748887)
21. Barbareschi M, Buttitta F, Felicioni L,Cotrupi S, Barassi F, et al. (2007) Different prognostic roles of mutations in the helical and kinase domains of the PIK3CA gene in breast carcinomas. Clin Cancer Res 13: 6064-9. (Pubitemid 350075063)
22. Baselga J, Cortés J, Im S-A, Clark E, Kiermaier A, et al. (2012) Biomarker Analyses in CLEOPATRA: A Phase III, Placebo-Controlled Study of Pertuzumab in HER2-Positive, First-Line Metastatic Breast Cancer (MBC). Cancer Research: December 15, 2012; Volume 72, Issue 24, Supplement 3.
23. Ramirez-Ardila D, Helmijr JC, Look MP, Lurkin I, Ruigrok-Ritstier K, et al. (2013) Hotspot mutations in PIK3CA predict treatment outcome on Aromatase Inhibitors but are not predictive for Tamoxifen. Breast Cancer Res Treat 139: 39-49
24. Castellvi J, Garcia A, Rojo F, Ruiz-Marcellan C, Gil A, Baselga J, et al. (2006) Phosphorylated 4E binding protein 1: a hallmark of cell signaling that correlates with survival in ovarian cancer. Cancer 107: 1801-11. (Pubitemid 44582949)
25. Hortobagyi GN, Piccart-Gebhart MJ, Rugo S . Hope, Burris A . Howard, Campone Mario, et al. (2013) Correlation of molecular alterations with efficacy of everolimus in hormone receptor-positive, HER2-negative advanced breast cancer: Results from BOLERO-2. J Clin Oncol 31, (suppl; abstr LBA509).
26. Dong Y, Yang X, Wong O, Zhang X, Liang Y, et al. (2011) PIK3CA mutations in endometrial carcinomas in Chinese women: phosphatidylinositol 3′-kinase pathway alterations might be associated with favorable prognosis. Hum Pathol 43: 1197-205.
27. Kalinsky K, Jacks LM, Heguy A, Patil S, Drobnjak M, et al. (2009) PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res 15: 5049-59.
28. Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, et al.(2008) An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res 68: 6084-91.
29. Li SY, Rong M, Grieu F, Iacopetta B (2006) PIK3CA mutations in breast cancer are associated with poor outcome. Breast Cancer Res Treat 96: 91-5.
30. Lai YL, Mau BL, Cheng WH, Chen HM, Chiu HH, et al. (2008) PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients. Ann Surg Oncol 15: 1064-9.
31. Kirkegaard T, Witton CJ, McGlynn LM, Tovey SM, Dunne B, et al. (2005) AKT activation predicts outcome in breast cancer patients treated with tamoxifen. J Pathol 207: 139-46. (Pubitemid 41404144)
32. Oh MH, Lee HJ, Yoo SB, Xu X, Choi JS, et al. (2012) Clinicopathological correlations of mTOR and pAkt expression in non-small cell lung cancer. Virchows Arch 460: 601-9.
33. Xiao L, Wang YC, Li WS, Du Y (2009) The role of mTOR and phosphop70S6K in pathogenesis and progression of gastric carcinomas: an immunohistochemical study on tissue microarray. J Exp Clin Cancer Res 28:152.
34. Yu Z, Weinberger PM, Sasaki C, Egleston BL, Speier WF 4th, et al. (2007) Phosphorylation of Akt (Ser473) predicts poor clinical outcome in oropharyngeal squamous cell cancer. Cancer Epidemiol Biomarkers Prev 16: 553-8. (Pubitemid 46548660)
35. Yu G, Wang J, Chen Y, Wang X, Pan J, et al. (2009) Overexpression of phosphorylated mammalian target of rapamycin predicts lymph node metastasis and prognosis of chinese patients with gastric cancer. Clin Cancer Res 15: 1821-9.
36. Hsu CP, Kao TY, Chang WL, Nieh S, Wang HL, Chung YC (2011) Clinical significance of tumor suppressor PTEN in colorectal carcinoma. Eur J Surg Oncol 37: 140-7.
37. Lotan TL, Gurel B, Sutcliffe S, Esopi D, Liu W, et al. (2011) PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res 17: 6563-73.
38. Sawai H, Yasuda A, Ochi N, Ma J, Matsuo Y, et al. (2008). Loss of PTEN expression is associated with colorectal cancer liver metastasis and poor patient survival. BMC Gastroenterol 26; 8:56.
39. Sze KM, Wong KL, Chu GK, Lee JM, Yau TO, et al. (2011) Loss of phosphatase and tensin homolog enhances cell invasion and migration through AKT/Sp-1 transcription factor/matrix metalloproteinase 2 activation in hepatocellular carcinoma and has clinicopathologic significance. Hepatology 53: 1558-69.
40. Terakawa N, Kanamori Y, Yoshida S (2003) Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer. Endocr Relat Cancer 10: 203-8. (Pubitemid 36758649)